tiprankstipranks
Carrick Therapeutics closes $25M Series C financing
The Fly

Carrick Therapeutics closes $25M Series C financing

Carrick Therapeutics announced it has raised $25 million in a Series C financing. The financing round was supported by existing investors, including ARCH Venture Partners, Rosetta Capital, Lightstone Ventures, Google Ventures (GOOG, GOOGL), Cambridge Innovation Capital, and Evotec (EVO). The Company intends to use the proceeds to fund ongoing and planned samuraciclib clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes. Carrick has raised a total of $60 million from the Series C financing and Pfizer (PFE) investment. The Company recently announced Pfizer Inc. has made a $35 million investment in Carrick. Carrick will maintain full economic ownership and control of samuraciclib and the rest of its pipeline.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on PFE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles